Skip to main content

UTILIDAD DE LA BIOPSIA LIQUIDA EN EL DIAGNOSTICO MOLECULAR, SEGUIMIENTO Y MANEJO TERAPEUTICO DEL CARCINOMA HEPATOCELULAR

PI18/00961

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma

  • Pinato, David James|||0000-0002-3529-0103
  • Kaneko, Takahiro
  • D'Alessio, Antonio
  • Forner, Alejandro|||0000-0002-9014-4950
  • Fessas, Petros|||0000-0002-7472-8913
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Giannini, Edoardo G.
  • Grillo, Federica
  • Díaz, Alba|||0000-0002-0456-7085
  • Mauri, Francesco A.
  • Fulgenzi, Claudia A.M.
  • Dalla Pria, Alessia
  • Goldin, Robert D.
  • Pieri, Giulia
  • Toniutto, Pierluigi|||0000-0002-2566-3041
  • Avellini, Claudio
  • Plaz Torres, Maria Corina
  • Akarca, Ayse U.
  • Marafioti, Teresa
  • Bhoori, Sherrie
  • Miró, José M.|||0000-0001-8057-7755
  • Bower, Mark
  • Bräu, Norbert
  • Mazzaferro, Vincenzo|||0000-0002-4013-8085
HIV-seropositivity shortens survival in patients with hepatocellular carcinoma (HCC). Although risk factors for HCC including HCV infection can influence T cell phenotype, it is unknown whether HIV can influence functional characteristics of the T cell infiltrate. From the Liver Cancer in HIV biorepository, we derived 129 samples of transplanted (76%) or resected (20%) HCC in eight European and North American centres. We profiled intra- and peritumoural tissue to evaluate regulatory CD4+/FOXP3+ and immune-exhausted CD8+/PD1+ T cells in HIV+ (n = 66) and HIV- (n = 63) samples. We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples evaluated in relationship with HIV status. We correlated immunopathologic features with patients' characteristics including markers of HIV infection. Of the 66 HIV+ patients, 83% were HCV coinfected with an undetectable HIV viral load (51%) and a median blood CD4+ cell count of 430 cells/mm 3 (range 15-908). Patients who were HIV+ were compared with HIV- controls with similar staging characteristics including Barcelona Clinic Liver Cancer (BCLC) stage A-B (86% vs. 83%, p = 0.16), <3 nodules (90% vs. 83%, p = 0.3) and median alpha-foetoprotein values (10.9 vs. 12.8 ng/ml, p = 0.72). HIV+ samples had higher PD-L1 expression rates in tumour tissue (51% vs. 8% p <0.0001) and displayed denser intratumoural CD4+/FOXP3+ (p <0.0001), CD8+/PD1+ (p <0.0001), with lower total peritumoural CD4+ (p <0.0001) and higher peritumoural CD8+/PD1+ (p <0.0001). Gene set analysis revealed HIV+ cases to have evidence of dysregulated adaptive and innate immunity. Tumour-infiltrating lymphocyte clonality was not influenced by HIV status. HIV-associated HCC harbours a profoundly immune-exhausted tumour microenvironment, warranting prospective testing of immunotherapy in this treatment-deprived patient population. Hepatocellular carcinoma is a non-AIDS defining malignancy characterised by poor survival. The programmed cell death (PD-1) pathway governs antiviral and anticancer immune exhaustion and is a therapeutic target in HCC. This study highlights how HIV infection is associated with significantly higher PD-L1 expression in HCC cells and in the surrounding microenvironment, leading to changes in cytotoxic and regulatory T cell function and dysregulation of proinflammatory pathways. Taken together, our results suggest dysfunctional T cell immunity as a mechanism of worse outcome in these patients and suggest clinical testing of checkpoint inhibitors in HIV-associated HCC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evolving epidemiology of HCC in Spain

  • Sala Llinas, Margarita|||0000-0003-4879-1780
  • Pascual, Sonia|||0000-0002-4265-5019
  • Rota Roca, Maria Rosa
  • Matilla, Ana María
  • Campos, Marta
  • Delgado, Manuel
  • Ferrer, María Teresa
  • Montero, José Luís
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Guerrero, Antonio
  • Aracil, Carlos|||0000-0002-8228-9041
  • Rodríguez Lope, Carlos|||0000-0002-6713-8800
  • Romero-Gutiérrez, Marta
  • Sogbe, Miguel|||0000-0002-2846-7812
  • Vázquez Rodríguez, Sergio|||0000-0001-6108-9449
  • Fuentes Olmo, Javier|||0000-0001-8637-510X
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Cortés-García, Luis|||0000-0003-3164-2703
  • Vallejo-Senra, N.
  • Rendón, Paloma|||0000-0002-6521-3766
  • Clos, Ariadna|||0000-0002-6414-2097
  • Díaz-Bethencourt, D.
  • García Sánchez, Araceli
  • Quiñones Castro, Raisa|||0000-0003-2446-9068
  • Bustamante, Javier|||0000-0002-5280-3038
  • Perelló, Christie|||0000-0003-0234-2330
  • Urquijo Ponce, J.J.
  • Andreu Serra, Hernán
  • Llamoza-Torres, Camilo J.|||0000-0001-8072-9413
  • Montoliu, Silvia|||0000-0002-3041-578X
  • Fernández Marcos, Cristina
  • Guiberteau, A.
  • Hernandez-Guerra, Manuel|||0000-0002-3478-9981
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Fernández-López, A.M.
  • Valer López-Fando, M.P.
  • Gutiérrez-García, M.L.
  • Hernáez-Alsina, T.|||0000-0002-3734-2448
  • Coll, Susanna|||0000-0002-0395-9685
  • Cuyàs, Berta|||0000-0001-9988-7163
  • Morillas, M.J.
  • Rebolledo Olmedo, Susana
  • Fernández Bermejo, Miguel
  • Roget, Mercè
  • Calvo Ramos, Irina
  • Pacheco del Río, G.
  • Rifà, Raimon|||0000-0003-1911-3681
  • Conde Gacho, Pilar
  • Llorente Barrio, Mónica|||0000-0003-0267-989X
  • Gómez-Rubio, M.
  • Peñas, Irene
  • Serra Matamala, Isabel|||0000-0002-5694-9325
  • Cachero, Alba|||0000-0002-0010-4534
  • Reig, María|||0000-0002-5711-9534
  • Giráldez-Gallego, Álvaro|||0000-0001-6849-9272
  • Guerrero Misas, Marta
  • Segarra, J.X.|||0000-0002-7222-5191
  • Lledó, J.L.
  • Díaz-González, Álvaro|||0000-0003-3610-2263
  • Delgado, Carolina|||0000-0002-0808-4494
  • Iñarrairaegui, M.
  • Rodríguez-González, M.M.
  • Lázaro, M.
  • Bermúdez-Ramos, María|||0000-0002-5516-3902
  • Lué, A.|||0000-0002-9672-6038
  • Molina, E.
  • Macías-Rodríguez, M.A.|||0000-0003-2634-6125
  • Rodríguez, Manuel|||0000-0001-5763-7668
  • Chiminazzo, V.
  • Varela Calvo, Maria|||0000-0003-4288-2593
Background & Aims: The epidemiological landscape of hepatocellular carcinoma (HCC) in Europe is evolving. This study aims to provide an updated description of the current epidemiology of liver cancer in Spain. Methods: This multicenter prospective study collected demographic and clinical data on primary liver cancer between October 2022 and January 2023. We conducted descriptive and comparative analyses with data collected in 2008 and 2014. Results: Of the 767 cases of primary liver cancer collected from 52 centers, 91% were diagnosed as HCC. The majority of patients were male (83.3%), average age 68 years, 80.7% had cirrhosis. The primary causes were alcohol (29.9% alone, 55% combined with other etiologies), liver disease related to metabolic syndrome (LDrMS, 23%) and hepatitis C (17.3%). Treatments included ablation (15.7%), systemic therapy (14.7%), and chemoembolization (14.6%). Data from 29 centers (n = 1,351) across three registries revealed a significant increase in LDrMS (from 4.9% to 24%) and HCC in non-cirrhotic livers (from 4.2% to 7.9%). Meanwhile, hepatitis C decreased sharply (from 43% to 17.5%). Alcohol-related cases remained stable. There was a slight increase in male patients and hypertension, diabetes, and obesity. Patients with cirrhosis diagnosed outside of screening programs presented with larger tumors and more advanced disease. This led to fewer evaluations for curative treatments. Conclusions: Alcohol accounts for 30% of HCC cases and is the main etiology. The registry shows a decrease in hepatitis C-related HCC, an increase in LDrMS and HCC in non-cirrhotic livers. Surveillance was implemented in ∼80% of the recommended population. There is a need for improved screening and prevention strategies, particularly for alcohol abuse and LDrMS, to enhance HCC management. Impact and implications: Our study showcases the involvement of numerous reference centers across Spain and examines over 1,300 patients to track the changing epidemiology of hepatocellular carcinoma (HCC) over 14 years. In patients with known liver cirrhosis, more than 80% of HCC diagnoses were made through screening leading to early-stage identification and curative treatment opportunities. Notably, there has been a shift in HCC etiology within the registries from hepatitis C to liver disease related to metabolic syndrome, with an increase in cases without cirrhosis. Findings indicate a need for the prevention and early detection of HCC, particularly focusing on alcohol and liver disease related to metabolic syndrome, along with greater involvement of health authorities, to improve the participation of at-risk patients in screening programs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical Trial, Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)

  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Matilla, Ana
  • Lledó-Navarro, José Luis|||0000-0001-7973-3503
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Iñarrairaegui, Mercedes|||0000-0001-9180-4693
  • Perelló, Christie|||0000-0003-0234-2330
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Llarch, Neus|||0000-0003-3209-0453
  • Márquez, Laura
  • Guerrero, Antonio
  • Iserte, Gemma|||0000-0003-3908-8743
  • Castaño-García, Andrés|||0000-0002-7921-9026
  • Carrión, Laura
  • Fortuny, Marta
  • Rimola, Jordi|||0000-0002-1814-4198
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Domenech, Gema
  • Torres, Ferran|||0000-0002-7355-7913
  • Ríos, José|||0000-0002-0716-8784
  • Boix, Loreto|||0000-0002-6015-3901
  • Samper, Esther
  • Kateb, Àngels
  • Bruix, Jordi|||0000-0002-9826-0753
  • Reig, María|||0000-0002-5711-9534
BACKGROUND & AIMS: Highly effective second-line treatments for hepatocellular carcinoma remain an unmet need. The GOING investigator-initiated Phase I/IIa trial evaluated regorafenib plus nivolumab (add-on) in patients who progressed on sorafenib (Cohort-A) or discontinued atezolizumab-bevacizumab (Cohort-B). METHODS: Patients received regorafenib for two 28-day cycles, adding nivolumab in cycle 3, until unacceptable adverse events, symptomatic progression, withdrawal or death. Primary endpoint was safety. Secondary endpoints included overall survival, time to progression, post-progression survival, objective response rate and incidence of new-extrahepatic-spread. RESULTS: Of 85 patients screened, 67 were enrolled (75.5% BCLC-C). All experienced adverse events and 9% led to discontinuation. Severe treatment-related adverse events occurred in 28.4% overall, 32.1% in Cohort-A, and 14.3% in Cohort-B. Median overall survival was 20.0 (95% CI 11-37) months, with 40.6% survival at 36 months. In Cohort-A, median overall survival was 25 (95% CI 14-39) months with 45% survival at 36 months, while Cohort-B median overall survival was 8 (95% CI 4-NE) months with 28.6% survival at 24 months. Objective response rate was 16.4%; median time to progression and post-progression survival were 5 (95% CI 4-9) months and 14 (95% CI 8-33) months. Intrahepatic growth was the most common progression pattern, followed by new-extrahepatic-spread. CONCLUSIONS: The add-on strategy of regorafenib plus nivolumab in second-line had manageable safety and significant clinical activity with a noteworthy median overall survival of 20 months. Among those progressing on sorafenib, 45% were alive at 3 years. These findings support further evaluation with mechanism-guided trials after progression on immunotherapy. TRIAL REGISTRATION: EudraCT number: 2019-003108-10; https://www.clinicaltrialsregister.eu.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Harnessing Plasma Biomarkers to Predict Immunotherapy Outcomes in Hepatocellular Carcinoma: The Role of cfDNA, ctDNA, and Cytokines

  • Merino Casabiel, Xavier
  • Vargas Accarino, Elena
  • Higuera Urbano, Monica
  • Bermúdez-Ramos, Maria
  • Soriano, Agnès
  • Torrens Buscató, Maria
  • Pons, Mònica
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Minguez, Beatriz
Biomarkers; Hepatocellular carcinoma; Immunotherapy, Biomarcadors; Carcinoma hepatocel·lular; Immunoteràpia, Biomarcadores; Carcinoma hepatocelular; Inmunoterapia, Immunotherapy has improved survival in patients with advanced hepatocellular carcinoma (HCC); yet, objective radiological responses occur in only about 20% of cases, suggesting variable benefits. This study aimed to identify serologic markers predictive of response to immune checkpoint inhibitors (ICIs). A cohort of 38 advanced HCC patients receiving immunotherapy was prospectively analyzed. Levels of cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and cytokines were measured pre-treatment and three months post-treatment initiation. Genomic profiling of ctDNA was also conducted. Baseline levels of cfDNA and ctDNA effectively discriminated HCC patients based on their radiological response to ICIs. Additionally, individuals with pathologic mutations in the CDKN2A gene exhibited significantly reduced survival. Patients with progressive disease (PD) as their best radiological response had significantly fewer copy number variations (CNVs) than those with a radiological response. Furthermore, levels of IL10, PD1, and TGFβ assessed after three months of treatment showed significant variations correlating with survival status. In conclusion, the analysis of cfDNA, ctDNA, and cytokines may improve treatment selection for HCC patients by predicting their expected response to immunotherapies., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI21/00714 and PI18/00961 to B.M. and co-funded by the European Union. E.V.-A. is a recipient of a predoctoral fellowship from Instituto de Salud Carlos III (ISCIII) (FI18/00027).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Evolving epidemiology of HCC in Spain

  • Sala Llinas, Margarita
  • Pascual, Sonia
  • Rota Roca, Maria Rosa
  • Matilla, Ana María
  • Campos, Marta
  • Delgado, Manuel
  • Minguez, Beatriz
  • Bermúdez-Ramos, Maria
Etiology; Liver cancer; Surveillance, Etiología; Cáncer de hígado; Vigilancia, Etiologia; Càncer de fetge; Vigilància, Background & Aims The epidemiological landscape of hepatocellular carcinoma (HCC) in Europe is evolving. This study aims to provide an updated description of the current epidemiology of liver cancer in Spain. Methods This multicenter prospective study collected demographic and clinical data on primary liver cancer between October 2022 and January 2023. We conducted descriptive and comparative analyses with data collected in 2008 and 2014. Results Of the 767 cases of primary liver cancer collected from 52 centers, 91% were diagnosed as HCC. The majority of patients were male (83.3%), average age 68 years, 80.7% had cirrhosis. The primary causes were alcohol (29.9% alone, 55% combined with other etiologies), liver disease related to metabolic syndrome (LDrMS, 23%) and hepatitis C (17.3%). Treatments included ablation (15.7%), systemic therapy (14.7%), and chemoembolization (14.6%). Data from 29 centers (n = 1,351) across three registries revealed a significant increase in LDrMS (from 4.9% to 24%) and HCC in non-cirrhotic livers (from 4.2% to 7.9%). Meanwhile, hepatitis C decreased sharply (from 43% to 17.5%). Alcohol-related cases remained stable. There was a slight increase in male patients and hypertension, diabetes, and obesity. Patients with cirrhosis diagnosed outside of screening programs presented with larger tumors and more advanced disease. This led to fewer evaluations for curative treatments. Conclusions Alcohol accounts for 30% of HCC cases and is the main etiology. The registry shows a decrease in hepatitis C-related HCC, an increase in LDrMS and HCC in non-cirrhotic livers. Surveillance was implemented in ∼80% of the recommended population. There is a need for improved screening and prevention strategies, particularly for alcohol abuse and LDrMS, to enhance HCC management. Impact and implications Our study showcases the involvement of numerous reference centers across Spain and examines over 1,300 patients to track the changing epidemiology of hepatocellular carcinoma (HCC) over 14 years. In patients with known liver cirrhosis, more than 80% of HCC diagnoses were made through screening leading to early-stage identification and curative treatment opportunities. Notably, there has been a shift in HCC etiology within the registries from hepatitis C to liver disease related to metabolic syndrome, with an increase in cases without cirrhosis. Findings indicate a need for the prevention and early detection of HCC, particularly focusing on alcohol and liver disease related to metabolic syndrome, along with greater involvement of health authorities, to improve the participation of at-risk patients in screening programs., The Spanish Association for the Study of the Liver (AEEH) has supported the design of the database in the online digital platform (REDCap®) and the storage in an electronic file (https://aeeh.es/politica-de-privacidad/). Elena Avanzas, Ph.D, expert medical writer has reviewed all the content to ensure that the grammar and style sound natural in British English. BM received competitive grants from Instituto de Salud Carlos III (grant numbers PI18/00961 and PI21/00714) cofounded by the EU and a research grant from Laboratorios Viñas S.L. MR received grant support from Instituto de Salud Carlos III (PI18/0358 and PI22/01427), from Centro de Investigación Biomédica en Red - CIBER (Immune4Al, S2300092_3) and from the Spanish Association Against Cancer (AECC, PRYCO234831).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Miret Campos Varela, Isabel
  • Villagrasa Vilella, Ares Aurora
  • Simon-Talero Horga, Macarena
  • Riveiro Barciela, Maria del Mar
  • Ventura Cots, Meritxell
  • Álvarez López, Patricia
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan
  • Barreira Diaz, Ana
  • Biagetti Biagetti, Betina
  • Camps-Relats, Laura
  • Cocera Rodriguez, Raul
  • Dopazo Taboada, Cristina
  • Fernandez Pujol, Andrea
  • Jimenez Hernandez, Cesar
  • Matarín Jiménez, Maria del Mar
  • Jofra, Mariona
  • Gil, Clara
  • Gomez Gavara, Concepción
  • Guevara Cubas, Jorge Alonso
  • Lobo Alvarez, Beatriz
  • Malagelada Prats, Carolina
  • Martínez Campreciós, Joan
  • Pando Rau, Elizabeth
  • Perez-Lopez, Ana
  • Prio, Alba
  • Rivera Esteban, Jesus Manuel
  • Romero, Alba
  • Tasayco Huaman, Stephanie Solange
  • Vidal Gonzalez, Judit
  • Vidal Piñeiro, Laura
  • Minguez Rosique, Beatriz
  • Genescà Ferrer, Joan
  • Ciudin Mihai, Andreea
  • Barber Caselles, Claudia
  • Augustin Recio, Salvador
  • Aguilera Castro, Lara
  • Guagnozzi, Danila
  • Miret Alomar, Enric
  • Pigrau Pastor, Marc
  • Mayorga Ayala, Luis Fernando
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paràmetre d'atenuació controlat; Lesió hepàtica, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Parámetro de atenuación controlado; Daño hepático, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Controlled attenuation parameter; Liver injury, Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p < 0.001). In conclusion, mild liver damage is prevalent in COVID-19 patients, but neither ALT elevation nor liver steatosis influenced hard clinical outcomes. Elevated baseline AST is a strong predictor of hard outcomes, especially in patients ⩾65 years., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JG is a recipient of a Research Intensification grant from the Instituto de Salud Carlos III, Spain. MST and MVC are recipients of a Juan Rodés grant from the Instituto de Salud Carlos III. The work was partially funded by grants PI17/00310, PI18/00947, PI18/00961, and PI19/00330 from Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future” – Una manera de hacer Europa). CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management

  • Vargas Accarino, Elena
  • Torrens Buscató, Maria Margarita
  • Salcedo Allende, Maria Teresa
  • Martínez Campreciós, Joan
  • Torres Pérez, Gloria
  • Bermúdez Ramos, María
  • Bilbao Aguirre, Itxarone Izaskun
  • Guerrero Murillo, Mercedes
  • Serres Créixams, Xavier
  • Merino Casabiel, Xavier
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Minguez Rosique, Beatriz
  • Gregori Font, Josep
  • Higuera Urbano, Monica
Biomarkers; cfDNA; Liquid biopsy, Biomarcadores; cfDNA; Biopsia líquida, Biomarcadors; cfDNA; Biòpsia líquida, Background: Cell-free DNA (cfDNA) concentrations have been described to be inversely correlated with prognosis in cancer. Mutations in HCC-associated driver genes in cfDNA have been reported, but their relation with patient’s outcome has not been described. Our aim was to elucidate whether mutations found in cfDNA could be representative from those present in HCC tissue, providing the rationale to use the cfDNA to monitor HCC. Methods: Tumoral tissue, paired nontumor adjacent tissue and blood samples were collected from 30 HCC patients undergoing curative therapies. Deep sequencing targeting HCC driver genes was performed. Results: Patients with more than 2 ng/µL of cfDNA at diagnosis had higher mortality (mean OS 24.6 vs. 31.87 months, p = 0.01) (AUC = 0.782). Subjects who died during follow-up, had a significantly higher number of mutated genes (p = 0.015) and number of mutations (p = 0.015) on cfDNA. Number of mutated genes (p = 0.001), detected mutations (p = 0.001) in cfDNA and ratio (number of mutations/cfDNA) (p = 0.003) were significantly associated with recurrence. However, patients with a ratio (number of mutations/cfDNA) above 6 (long-rank p = 0.0003) presented a higher risk of recurrence than those with a ratio under 6. Detection of more than four mutations in cfDNA correlated with higher risk of death (long-rank p = 0.042). Conclusions: In summary, cfDNA and detection of prevalent HCC mutations could have prognostic implications in early-stage HCC patients, This research was funded by Instituto de Salud Carlos III (ISCIII) (PI18/00961) and (PI21/00714) to B.M. PI19/00301 by Instituto de Salud Carlos III (ISCIII) and Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297 to J.Q., E.V.-A. is a recipient of a predoctoral fellowship from Instituto de Salud Carlos III (ISCIII) (FI18/00027).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

ARMCX3 Mediates Susceptibility to Hepatic Tumorigenesis Promoted by Dietary Lipotoxicity

  • Mirra, Serena
  • Gavaldà i Navarro, Aleix|||0000-0001-8421-3174
  • Manso Sanz, Yasmina|||0000-0002-5788-4180
  • Higuera, Mónica|||0000-0002-3999-9603
  • Serrat, Román|||0000-0001-5530-2135
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Burgaya, Ferran|||0000-0002-6060-1081
  • Balibrea Del Castillo, José María|||0000-0002-0764-7179
  • Santamaría Monasterio, Eva|||0000-0003-0629-6175
  • Uriarte, Iker|||0000-0001-5237-7799
  • Berasain, Carmen|||0000-0001-7075-2476
  • Avila, Matias A.|||0000-0001-6570-3557
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Soriano García, Eduardo
  • Villarroya, Francesc|||0000-0003-1266-9142
An excess fat in the liver enhances the susceptibility to hepatic cancer. We found that Armcx3, a protein only known to date to play a role in neural development, is strongly increased in mouse liver in response to lipid availability and proliferation-inducing insults. In patients, the levels of hepatic Armcx3 are also increased in conditions of high exposure of the liver to fat. We wanted to determine the role of Armcx3 in the hepatocarcinogenesis favored by a high-fat diet. We generated mice with genetically driven suppression of Armcx3, and we found that they were protected against experimentally induced hepatic cancer, especially in conditions of a high-fat diet. Armcx3 was also found to promote hepatic cell proliferation through the interaction with Sox9, a known proliferation factor in hepatocellular carcinoma. Armcx3 is identified as a novel factor in meditating propensity to liver cancer in conditions of high hepatic lipid insults. ARMCX3 is encoded by a member of the Armcx gene family and is known to be involved in nervous system development and function. We found that ARMCX3 is markedly upregulated in mouse liver in response to high lipid availability, and that hepatic ARMCX3 is upregulated in patients with NAFLD and hepatocellular carcinoma (HCC). Mice were subjected to ARMCX3 invalidation (inducible ARMCX3 knockout) and then exposed to a high-fat diet and diethylnitrosamine-induced hepatocarcinogenesis. The effects of experimental ARMCX3 knockdown or overexpression in HCC cell lines were also analyzed. ARMCX3 invalidation protected mice against high-fat-diet-induced NAFLD and chemically induced hepatocarcinogenesis. ARMCX3 invalidation promoted apoptotic cell death and macrophage infiltration in livers of diethylnitrosamine-treated mice maintained on a high-fat diet. ARMCX3 downregulation reduced the viability, clonality and migration of HCC cell lines, whereas ARMCX3 overexpression caused the reciprocal effects. SOX9 was found to mediate the effects of ARMCX3 in hepatic cells, with the SOX9 interaction required for the effects of ARMCX3 on hepatic cell proliferation. In conclusion, ARMCX3 is identified as a novel molecular actor in liver physiopathology and carcinogenesis. ARMCX3 downregulation appears to protect against hepatocarcinogenesis, especially under conditions of high dietary lipid-mediated hepatic insult.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Villagrasa, Ares|||0000-0003-0928-0427
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Aguilera-Castro, Lara
  • Álvarez-López, Patricia|||0000-0003-4227-1987
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan|||0000-0002-1966-1947
  • Barber Caselles, Claudia|||0000-0003-4711-2731
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Biagetti, Betina|||0000-0002-8837-4343
  • Camps-Relats, Laura
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Cocera, Raul
  • Dopazo, Cristina|||0000-0001-6274-5911
  • Fernandez, Andrea
  • Jiménez, Cesar|||0000-0003-2455-2048
  • Jiménez, María M.
  • Jofra Castells, Mariona|||0000-0002-3034-4985
  • Gil, Clara
  • Gómez Gavara, Concepción|||0000-0001-8312-3273
  • Guanozzi, Danila
  • Guevara, Jorge A.
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Malagelada Prats, Carolina|||0000-0001-7097-1492
  • Martínez-Campreciós, Joan|||0000-0002-8899-8447
  • Mayorga, Luis
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Pando, Elizabeth|||0000-0001-6898-5502
  • Pérez-Lopez, Ana
  • Pigrau Pastor, Marc|||0000-0001-6801-3017
  • Prió, Alba
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Romero, Alba
  • Tasayco, Staphanie|||0000-0001-7867-349X
  • Vidal-Gonzalez, Judit
  • Vidal Piñeiro, Laura|||0000-0003-3757-3323
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management

  • Higuera, Mónica|||0000-0002-3999-9603
  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Torrens, Maria|||0000-0003-3479-0066
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Martínez-Campreciós, Joan|||0000-0002-8899-8447
  • Torres, Gloria
  • Bermúdez-Ramos, María|||0000-0002-5516-3902
  • Bilbao, Itxarone|||0000-0002-7389-395X
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Serres Creixams, Xavier|||0000-0001-8642-467X
  • Merino, Xavier|||0000-0002-1985-9363
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Quer, Josep|||0000-0003-0014-084X
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
In this unicentric prospective study, we analyzed the most prevalent mutations in HCC (TERT promoter, TP53, CTNNB1, AXIN1 and ARID1A) in plasma cfDNA by next-generation sequencing, aiming to elucidate their value as prognostic noninvasive biomarkers. Total cfDNA (cut-off value 2 ng/µL), number of mutated genes and number of detectable mutations on cfDNA were significantly related to mortality. Number of mutated genes and number of detected mutations in cfDNA and the ratio between number of mutations and total amount of cfDNA were also significantly associated with recurrence. Detection of more than four mutations in cfDNA correlated with a higher risk of death. Dynamic changes in cfDNA mutations were detected prior to radiological detection of HCC recurrence. We believe that these results support the proof of principle and launching of validation studies to confirm that total cfDNA and detection of prevalent HCC mutations could have prognostic implications in early-stage HCC patients. Background: Cell-free DNA (cfDNA) concentrations have been described to be inversely correlated with prognosis in cancer. Mutations in HCC-associated driver genes in cfDNA have been reported, but their relation with patient's outcome has not been described. Our aim was to elucidate whether mutations found in cfDNA could be representative from those present in HCC tissue, providing the rationale to use the cfDNA to monitor HCC. Methods: Tumoral tissue, paired nontumor adjacent tissue and blood samples were collected from 30 HCC patients undergoing curative therapies. Deep sequencing targeting HCC driver genes was performed. Results: Patients with more than 2 ng/µL of cfDNA at diagnosis had higher mortality (mean OS 24.6 vs. 31.87 months, p = 0.01) (AUC = 0.782). Subjects who died during follow-up, had a significantly higher number of mutated genes (p = 0.015) and number of mutations (p = 0.015) on cfDNA. Number of mutated genes (p = 0.001), detected mutations (p = 0.001) in cfDNA and ratio (number of mutations/cfDNA) (p = 0.003) were significantly associated with recurrence. However, patients with a ratio (number of mutations/cfDNA) above 6 (long-rank p = 0.0003) presented a higher risk of recurrence than those with a ratio under 6. Detection of more than four mutations in cfDNA correlated with higher risk of death (long-rank p = 0.042). Conclusions: In summary, cfDNA and detection of prevalent HCC mutations could have prognostic implications in early-stage HCC patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

  • Soria, Anna|||0000-0001-5671-8343
  • Calvo, Mariona|||0000-0001-6242-0500
  • Casas, Meritxell|||0000-0001-7227-7277
  • Vidales, Zara
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • Puigvehí, Marc|||0000-0002-3694-3241
  • Canillas, Lidia
  • Guardeño, Raquel
  • Gallego Moya, Adolfo|||0000-0002-8423-6787
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Horta Sangenís, Diana|||0000-0002-3675-1135
  • Clos, Ariadna|||0000-0002-6414-2097
  • Montoliu, Silvia|||0000-0002-3041-578X
  • Roget, Mercè
  • Reig, María|||0000-0002-5711-9534
  • Vergara, Mercedes|||0000-0002-6971-8657
The first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under systemic treatment. The aims of this study were to characterize the profile of elderly patients treated with sorafenib, assess their survival and safety profile in order to extrapolate their eligibility for systemic treatment. Retrospective multicentre study of HCC patients aged ≥75 years old treated with sorafenib from January 2008 to December 2019. Demographic data, baseline characteristics, and variables related to HCC and sorafenib were recorded. Overall survival (OS) and safety were analyzed. The study included 206 patients from 11 hospitals, median age 77.9 years; 71.4% men and 62.6% stage Barcelona Clinic Liver Cancer- C (BCLC-C). The main causes of cirrhosis were hepatitis C (60.7%) and alcohol (14.7%). Most patients (84.5%) started with sorafenib 800mg and 15.5% at lower dosage. Arterial hypertension (AHT) (74.2 vs 62.2%; standardized mean differences (STD): 26) and baseline ECOG-PS.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Evolving epidemiology of HCC in Spain

  • Sala Llinas, Margarita
  • Pascual, Sonia
  • Rota Roca, Maria Rosa
  • Matilla, Ana María
  • Campos, Marta
  • Delgado, Manuel
  • Minguez, Beatriz
  • Bermúdez-Ramos, Maria
Etiology; Liver cancer; Surveillance, Etiología; Cáncer de hígado; Vigilancia, Etiologia; Càncer de fetge; Vigilància, Background & Aims The epidemiological landscape of hepatocellular carcinoma (HCC) in Europe is evolving. This study aims to provide an updated description of the current epidemiology of liver cancer in Spain. Methods This multicenter prospective study collected demographic and clinical data on primary liver cancer between October 2022 and January 2023. We conducted descriptive and comparative analyses with data collected in 2008 and 2014. Results Of the 767 cases of primary liver cancer collected from 52 centers, 91% were diagnosed as HCC. The majority of patients were male (83.3%), average age 68 years, 80.7% had cirrhosis. The primary causes were alcohol (29.9% alone, 55% combined with other etiologies), liver disease related to metabolic syndrome (LDrMS, 23%) and hepatitis C (17.3%). Treatments included ablation (15.7%), systemic therapy (14.7%), and chemoembolization (14.6%). Data from 29 centers (n = 1,351) across three registries revealed a significant increase in LDrMS (from 4.9% to 24%) and HCC in non-cirrhotic livers (from 4.2% to 7.9%). Meanwhile, hepatitis C decreased sharply (from 43% to 17.5%). Alcohol-related cases remained stable. There was a slight increase in male patients and hypertension, diabetes, and obesity. Patients with cirrhosis diagnosed outside of screening programs presented with larger tumors and more advanced disease. This led to fewer evaluations for curative treatments. Conclusions Alcohol accounts for 30% of HCC cases and is the main etiology. The registry shows a decrease in hepatitis C-related HCC, an increase in LDrMS and HCC in non-cirrhotic livers. Surveillance was implemented in ∼80% of the recommended population. There is a need for improved screening and prevention strategies, particularly for alcohol abuse and LDrMS, to enhance HCC management. Impact and implications Our study showcases the involvement of numerous reference centers across Spain and examines over 1,300 patients to track the changing epidemiology of hepatocellular carcinoma (HCC) over 14 years. In patients with known liver cirrhosis, more than 80% of HCC diagnoses were made through screening leading to early-stage identification and curative treatment opportunities. Notably, there has been a shift in HCC etiology within the registries from hepatitis C to liver disease related to metabolic syndrome, with an increase in cases without cirrhosis. Findings indicate a need for the prevention and early detection of HCC, particularly focusing on alcohol and liver disease related to metabolic syndrome, along with greater involvement of health authorities, to improve the participation of at-risk patients in screening programs., The Spanish Association for the Study of the Liver (AEEH) has supported the design of the database in the online digital platform (REDCap®) and the storage in an electronic file (https://aeeh.es/politica-de-privacidad/). Elena Avanzas, Ph.D, expert medical writer has reviewed all the content to ensure that the grammar and style sound natural in British English. BM received competitive grants from Instituto de Salud Carlos III (grant numbers PI18/00961 and PI21/00714) cofounded by the EU and a research grant from Laboratorios Viñas S.L. MR received grant support from Instituto de Salud Carlos III (PI18/0358 and PI22/01427), from Centro de Investigación Biomédica en Red - CIBER (Immune4Al, S2300092_3) and from the Spanish Association Against Cancer (AECC, PRYCO234831).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management

  • Vargas Accarino, Elena
  • Torrens Buscató, Maria Margarita
  • Salcedo Allende, Maria Teresa
  • Martínez Campreciós, Joan
  • Torres Pérez, Gloria
  • Bermúdez Ramos, María
  • Bilbao Aguirre, Itxarone Izaskun
  • Guerrero Murillo, Mercedes
  • Serres Créixams, Xavier
  • Merino Casabiel, Xavier
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Minguez Rosique, Beatriz
  • Gregori Font, Josep
  • Higuera Urbano, Monica
Biomarkers; cfDNA; Liquid biopsy, Biomarcadores; cfDNA; Biopsia líquida, Biomarcadors; cfDNA; Biòpsia líquida, Background: Cell-free DNA (cfDNA) concentrations have been described to be inversely correlated with prognosis in cancer. Mutations in HCC-associated driver genes in cfDNA have been reported, but their relation with patient’s outcome has not been described. Our aim was to elucidate whether mutations found in cfDNA could be representative from those present in HCC tissue, providing the rationale to use the cfDNA to monitor HCC. Methods: Tumoral tissue, paired nontumor adjacent tissue and blood samples were collected from 30 HCC patients undergoing curative therapies. Deep sequencing targeting HCC driver genes was performed. Results: Patients with more than 2 ng/µL of cfDNA at diagnosis had higher mortality (mean OS 24.6 vs. 31.87 months, p = 0.01) (AUC = 0.782). Subjects who died during follow-up, had a significantly higher number of mutated genes (p = 0.015) and number of mutations (p = 0.015) on cfDNA. Number of mutated genes (p = 0.001), detected mutations (p = 0.001) in cfDNA and ratio (number of mutations/cfDNA) (p = 0.003) were significantly associated with recurrence. However, patients with a ratio (number of mutations/cfDNA) above 6 (long-rank p = 0.0003) presented a higher risk of recurrence than those with a ratio under 6. Detection of more than four mutations in cfDNA correlated with higher risk of death (long-rank p = 0.042). Conclusions: In summary, cfDNA and detection of prevalent HCC mutations could have prognostic implications in early-stage HCC patients, This research was funded by Instituto de Salud Carlos III (ISCIII) (PI18/00961) and (PI21/00714) to B.M. PI19/00301 by Instituto de Salud Carlos III (ISCIII) and Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297 to J.Q., E.V.-A. is a recipient of a predoctoral fellowship from Instituto de Salud Carlos III (ISCIII) (FI18/00027).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Miret Campos Varela, Isabel
  • Villagrasa Vilella, Ares Aurora
  • Simon-Talero Horga, Macarena
  • Riveiro Barciela, Maria del Mar
  • Ventura Cots, Meritxell
  • Álvarez López, Patricia
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan
  • Barreira Diaz, Ana
  • Biagetti Biagetti, Betina
  • Camps-Relats, Laura
  • Cocera Rodriguez, Raul
  • Dopazo Taboada, Cristina
  • Fernandez Pujol, Andrea
  • Jimenez Hernandez, Cesar
  • Matarín Jiménez, Maria del Mar
  • Jofra, Mariona
  • Gil, Clara
  • Gomez Gavara, Concepción
  • Guevara Cubas, Jorge Alonso
  • Lobo Alvarez, Beatriz
  • Malagelada Prats, Carolina
  • Martínez Campreciós, Joan
  • Pando Rau, Elizabeth
  • Perez-Lopez, Ana
  • Prio, Alba
  • Rivera Esteban, Jesus Manuel
  • Romero, Alba
  • Tasayco Huaman, Stephanie Solange
  • Vidal Gonzalez, Judit
  • Vidal Piñeiro, Laura
  • Minguez Rosique, Beatriz
  • Genescà Ferrer, Joan
  • Ciudin Mihai, Andreea
  • Barber Caselles, Claudia
  • Augustin Recio, Salvador
  • Aguilera Castro, Lara
  • Guagnozzi, Danila
  • Miret Alomar, Enric
  • Pigrau Pastor, Marc
  • Mayorga Ayala, Luis Fernando
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paràmetre d'atenuació controlat; Lesió hepàtica, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Parámetro de atenuación controlado; Daño hepático, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Controlled attenuation parameter; Liver injury, Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p < 0.001). In conclusion, mild liver damage is prevalent in COVID-19 patients, but neither ALT elevation nor liver steatosis influenced hard clinical outcomes. Elevated baseline AST is a strong predictor of hard outcomes, especially in patients ⩾65 years., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JG is a recipient of a Research Intensification grant from the Instituto de Salud Carlos III, Spain. MST and MVC are recipients of a Juan Rodés grant from the Instituto de Salud Carlos III. The work was partially funded by grants PI17/00310, PI18/00947, PI18/00961, and PI19/00330 from Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future” – Una manera de hacer Europa). CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Harnessing Plasma Biomarkers to Predict Immunotherapy Outcomes in Hepatocellular Carcinoma: The Role of cfDNA, ctDNA, and Cytokines

  • Merino Casabiel, Xavier
  • Vargas-Accarino, Elena
  • Higuera Urbano, Monica
  • Bermúdez-Ramos, Maria
  • Soriano, Agnès
  • Torrens Buscató, Maria
  • Pons, Mònica
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Minguez, Beatriz
Biomarkers; Hepatocellular carcinoma; Immunotherapy, Biomarcadors; Carcinoma hepatocel·lular; Immunoteràpia, Biomarcadores; Carcinoma hepatocelular; Inmunoterapia, Immunotherapy has improved survival in patients with advanced hepatocellular carcinoma (HCC); yet, objective radiological responses occur in only about 20% of cases, suggesting variable benefits. This study aimed to identify serologic markers predictive of response to immune checkpoint inhibitors (ICIs). A cohort of 38 advanced HCC patients receiving immunotherapy was prospectively analyzed. Levels of cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and cytokines were measured pre-treatment and three months post-treatment initiation. Genomic profiling of ctDNA was also conducted. Baseline levels of cfDNA and ctDNA effectively discriminated HCC patients based on their radiological response to ICIs. Additionally, individuals with pathologic mutations in the CDKN2A gene exhibited significantly reduced survival. Patients with progressive disease (PD) as their best radiological response had significantly fewer copy number variations (CNVs) than those with a radiological response. Furthermore, levels of IL10, PD1, and TGFβ assessed after three months of treatment showed significant variations correlating with survival status. In conclusion, the analysis of cfDNA, ctDNA, and cytokines may improve treatment selection for HCC patients by predicting their expected response to immunotherapies., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI21/00714 and PI18/00961 to B.M. and co-funded by the European Union. E.V.-A. is a recipient of a predoctoral fellowship from Instituto de Salud Carlos III (ISCIII) (FI18/00027).